SCHEMBL3824312

SCHEMBL3824312

Cc1ccccc1-c1cccc(C(=O)O)c1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.66
ALDH1A1 P00352 6/20 0.52
HPGD P15428 3/20 0.52
HSD17B10 Q99714 3/20 0.52
KDM4E B2RXH2 2/20 0.52
G6PD P11413 1/20 0.52
CASP7 P55210 1/20 0.52
CASP6 P55212 1/20 0.52
MCL1 Q07820 1/20 0.49
KMT2A Q03164 3/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
POLB P06746 2/20 0.47
FABP4 P15090 1/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
AKR1B10 O60218 1/20 0.46
TRPA1 O75762 1/20 0.46
ABCB11 O95342 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3825800 0.88 MYC (0.59) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL7851664 0.87 MYC (0.73) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL17744802 0.87 G6PD (0.61) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL9851131 0.87 G6PD (0.65) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3701689 0.86 MYC (0.51) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL8061730 0.83 MYC (0.54) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL130355 0.83 KDM4E (0.61) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL29367017 0.83 KDM4E (0.61) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL30755384 0.83 MYC (0.71) MYCALDH1A1HPGDHSD17B10KDM4E
SCHEMBL656 0.83 MYC (0.71) MYCALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2021-11-18 US disclosed
US-9872846-B2 High penetration compositions and uses thereof TECHFIELDS PHARMA CO., LTD. (CN) 2018-01-23 US disclosed
US-20170209585-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2017-07-27 US disclosed
US-20170209404-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF PREMIER RESEARCH INTERNATIONAL, LLC 2017-07-27 US disclosed
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO., LTD. (CN) 2009-09-24 US disclosed
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-05-21 US disclosed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME CLIC1, ASIC1, CLIC4 MYC 4475/4885ALDH1A1 1179/4885HPGD 2548/4885
US-20170209404-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES MYC 4386/4885ALDH1A1 1790/4885HPGD 17/4885
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES MYC 4386/4885ALDH1A1 1790/4885HPGD 17/4885
US-20170209585-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES MYC 4386/4885ALDH1A1 1790/4885HPGD 17/4885
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES MYC 4386/4885ALDH1A1 1790/4885HPGD 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.